Mary Dillahunty, vice president of intellectual property at Oncolytics, said: “This patent provides the company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada.”
Mary Dillahunty, vice president of intellectual property at Oncolytics, said: “This patent provides the company with additional patent protection for the use of reovirus compositions for cancers and other cellular proliferative disorders in Canada.”